OverviewSuggest Edit

Alector is a clinical-stage biopharmaceutical company that develops therapies for the treatment of neurodegenerative diseases. It offers AL001, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease.

TypePublic
Founded2013
HQSouth San Francisco, CA, US
Websitealector.com

Latest Updates

Employees (est.) (Mar 2020)126(+5%)
Revenue (FY, 2019)$21.2 M(-23%)
Share Price (Jan 2021)$15.5 (+2%)
Cybersecurity ratingBMore

Key People/Management at Alector

Arnon Rosenthal

Arnon Rosenthal

Chief Executive Officer, Co-Founder
Spencer LIang

Spencer LIang

Senior Director, Research – Immuno-Oncolocy
Shehnaaz Suliman

Shehnaaz Suliman

President and Chief Operating Officer
Robert King

Robert King

Chief Development Officer
Sabah Oney

Sabah Oney

Chief Business Officer
Robert Paul

Robert Paul

Chief Medical Officer & Director
Show more

Alector Office Locations

Alector has offices in South San Francisco and Milpitas
South San Francisco, CA, US (HQ)
131 Oyster Point Blvd #600
Milpitas, CA, US
521 Cottonwood Dr #112
Show all (2)

Alector Financials and Metrics

Alector Revenue

Alector's revenue was reported to be $21.22 m in FY, 2019 which is a 23.3% decrease from the previous period.
USD

Revenue (Q2, 2020)

3.2m

Net income (Q2, 2020)

(45.3m)

EBIT (Q2, 2020)

(46.6m)

Market capitalization (14-Jan-2021)

1.2b

Closing stock price (14-Jan-2021)

15.5

Cash (30-Jun-2020)

92.5m

EV

1.2b
Alector's current market capitalization is $1.2 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

3.7m27.7m21.2m

Revenue growth, %

798%641%(23%)

General and administrative expense

6.5m11.9m35.1m

R&D expense

29.9m73.0m100.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

4.8m7.1m2.7m5.6m6.9m2.7m7.2m3.2m

General and administrative expense

2.4m2.5m8.3m5.8m8.4m8.3m14.6m15.7m

R&D expense

11.7m16.8m28.5m20.6m25.6m28.5m34.6m34.1m

Operating expense total

14.1m19.3m36.8m26.4m34.1m36.8m49.2m49.8m
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

32.5m65.5m89.6m

Accounts Receivable

238.0k

Prepaid Expenses

285.0k2.8m4.4m

Current Assets

233.0m293.2m357.4m
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

41.9m61.0m69.2m87.0m160.9m92.5m

Prepaid Expenses

3.9m5.5m3.7m4.0m7.7m6.4m

Current Assets

312.6m442.1m414.6m385.5m556.2m510.1m

PP&E

3.6m21.7m32.0m33.9m32.7m31.5m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(32.5m)(52.2m)(105.4m)

Depreciation and Amortization

680.0k1.0m3.8m

Accounts Payable

(41.0k)(809.0k)152.0k

Cash From Operating Activities

(17.8m)127.5m(99.3m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(8.4m)(19.6m)(34.9m)(18.6m)(43.1m)(74.9m)(40.0m)(85.3m)

Depreciation and Amortization

212.0k464.0k743.0k298.0k1.1m2.4m1.4m2.9m

Accounts Payable

(783.0k)(830.0k)(604.0k)683.0k414.0k132.0k3.1m4.4m

Cash From Operating Activities

184.5m167.5m145.1m(23.6m)(41.6m)(70.5m)(32.3m)(78.3m)
USDFY, 2017

Financial Leverage

-4.5 x
Show all financial metrics

Alector Operating Metrics

FY, 2018FY, 2019

Immune System Targets Identified to Date

120

Patent Applications

100 190

Patent Families

25 30

Product Candidates

4
Show all operating metrics

Alector Acquisitions / Subsidiaries

Company NameDateDeal Size
Alector LLC

Alector Revenue Breakdown

Embed Graph

Alector revenue breakdown by business segment: 100.0% from Collaboration

Alector Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Alector Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Alector Online and Social Media Presence

Embed Graph

Alector News and Updates

Alector Provides 2021 Corporate Portfolio Update

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today provided a preview of its planned clinical and research priorities for 2021.

Alector to Highlight Early-Stage Cancer Programs at Upcoming Scientific Forums

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of the Company’s immuno-oncology team will provide an overview of the company’s early-stage immuno-oncology re…

Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced preliminary data from its Phase 1b and open-label Phase 2 studies of AL001, for the treatment of people with frontotempor…

Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia

SOUTH SAN FRANCISCO, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced dosing of the first patient in its pivotal Phase 3 clinical trial, named INFRONT-3, evaluating AL001 in people at risk fo…

What Kind Of Shareholder Owns Most Alector, Inc. (NASDAQ:ALEC) Stock?

Every investor in Alector, Inc. (NASDAQ:ALEC) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders.

Analysts Have Made A Financial Statement On Alector, Inc.'s (NASDAQ:ALEC) First-Quarter Report

The analysts might have been a bit too bullish on Alector, Inc. (NASDAQ:ALEC), given that the company fell short of expectations when it released its quarterly results last week.
Show more

Alector Frequently Asked Questions

  • When was Alector founded?

    Alector was founded in 2013.

  • Who are Alector key executives?

    Alector's key executives are Arnon Rosenthal, Spencer LIang and Shehnaaz Suliman.

  • How many employees does Alector have?

    Alector has 126 employees.

  • What is Alector revenue?

    Latest Alector annual revenue is $21.2 m.

  • What is Alector revenue per employee?

    Latest Alector revenue per employee is $168.4 k.

  • Who are Alector competitors?

    Competitors of Alector include Verge Genomics, Encoded Therapeutics and NKMax.

  • Where is Alector headquarters?

    Alector headquarters is located at 131 Oyster Point Blvd #600, South San Francisco.

  • Where are Alector offices?

    Alector has offices in South San Francisco and Milpitas.

  • How many offices does Alector have?

    Alector has 2 offices.